<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">medsovet</journal-id><journal-title-group><journal-title xml:lang="ru">Медицинский Совет</journal-title><trans-title-group xml:lang="en"><trans-title>Meditsinskiy sovet = Medical Council</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2079-701X</issn><issn pub-type="epub">2658-5790</issn><publisher><publisher-name>REMEDIUM GROUP Ltd.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.21518/2079-701X-2018-6-44-49</article-id><article-id custom-type="elpub" pub-id-type="custom">medsovet-2371</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>НЕВРОЛОГИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>NEUROLOGY</subject></subj-group></article-categories><title-group><article-title>Сравнительный анализ применения различных вариантов дополнительной фармакотерапии при болях в спине с точки зрения фармакоэкономического анализа</article-title><trans-title-group xml:lang="en"><trans-title>Pharmacoeconomic analysis of various adjunctive pharmacotherapy strategies for back pain using comparative method</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Балунов</surname><given-names>П. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Balunov</surname><given-names>P. A.</given-names></name></name-alternatives><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru">«Ремедиум»<country>Россия</country></aff><aff xml:lang="en">Remedium<country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2018</year></pub-date><pub-date pub-type="epub"><day>12</day><month>04</month><year>2018</year></pub-date><volume>0</volume><issue>6</issue><fpage>44</fpage><lpage>49</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Балунов П.А., 2018</copyright-statement><copyright-year>2018</copyright-year><copyright-holder xml:lang="ru">Балунов П.А.</copyright-holder><copyright-holder xml:lang="en">Balunov P.A.</copyright-holder><license license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.med-sovet.pro/jour/article/view/2371">https://www.med-sovet.pro/jour/article/view/2371</self-uri><abstract><p>Одной из причин инвалидности во всем мире являются заболевания позвоночника. Боль в спине – один из важнейших факторов, снижающих качество жизни пациентов. Правильный выбор фармакотерапии в совокупности с другими медицинскими технологиями – залог положительного лечения. Помимо препаратов, снимающих болевой синдром, большое внимание должно быть уделено восстановлению хрящевой ткани в позвоночнике. В данной работе проведен сравнительный фармакоэкономический анализ применения препаратов хондроитина и глюкозамина как дополнительной терапии при боли в спине.</p><p> </p></abstract><trans-abstract xml:lang="en"><p>Spinal disorders are one of the leading causes of disability worldwide. Back pain is one of the most important factors that reduce the patients’ quality of life. The right choice of pharmacotherapy in conjunction with other medical technologies is the key to successful treatment. In addition to drugs that relieve pain, much attention should be paid to the restoration of cartilage in the spine. This paper presents a comparative pharmacoeconomic analysis of the use of chondroitin and glucosamine as the adjunctive therapy.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>боль в спине</kwd><kwd>хондропротекторы</kwd><kwd>хондроитин</kwd><kwd>глюкозамин</kwd><kwd>фармакоэкономика</kwd></kwd-group><kwd-group xml:lang="en"><kwd>back pain</kwd><kwd>chondroprotectors</kwd><kwd>chondroitin</kwd><kwd>glucosamine</kwd><kwd>pharmacoeconomics</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Chou R, Côté P, Randhawa K et al. The Global Spine Care Initiative: applying evidence-based guidelines on the non-invasive management of back and neck pain to low-and middle-income communities. Eur Spine J, 2018.</mixed-citation><mixed-citation xml:lang="en">Chou R, Côté P, Randhawa K et al. The Global Spine Care Initiative: applying evidence-based guidelines on the non-invasive management of back and neck pain to low-and middle-income communities. Eur Spine J, 2018.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Global Burden of Disease 2013 Collaborators (2013) Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet, 2013, 386(9995): 743-800.</mixed-citation><mixed-citation xml:lang="en">Global Burden of Disease 2013 Collaborators (2013) Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet, 2013, 386(9995): 743-800.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Hogg-Johnson S, van der Velde G, Carroll LJ, Holm LW, Cassidy JD, Guzman J, Côté P, Haldeman S, Ammendolia C, Carragee E, Hurwitz E, Nordin M, Peloso P. The burden and determinants of neck pain in the general population: results of the Bone and Joint Decade 2000– 2010 Task Force on Neck Pain and Its Associated Disorders. Spine, 2008, 33(4 Suppl): 39-51.</mixed-citation><mixed-citation xml:lang="en">Hogg-Johnson S, van der Velde G, Carroll LJ, Holm LW, Cassidy JD, Guzman J, Côté P, Haldeman S, Ammendolia C, Carragee E, Hurwitz E, Nordin M, Peloso P. The burden and determinants of neck pain in the general population: results of the Bone and Joint Decade 2000– 2010 Task Force on Neck Pain and Its Associated Disorders. Spine, 2008, 33(4 Suppl): 39-51.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Hoy D, Brooks P, Blyth F, Buchbinder R. The Epi demio logy of low back pain. Best practice &amp; re search. Clinical rheumatology, 2010 Dec, 24(6): 769-781.</mixed-citation><mixed-citation xml:lang="en">Hoy D, Brooks P, Blyth F, Buchbinder R. The Epi demio logy of low back pain. Best practice &amp; re search. Clinical rheumatology, 2010 Dec, 24(6): 769-781.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Walker BF, Muller R, Grant WD. Low back pain in Australian adults: prevalence and associated disability. J Manipulative Physiol Ther, 2004 May, 27(4): 238-244.</mixed-citation><mixed-citation xml:lang="en">Walker BF, Muller R, Grant WD. Low back pain in Australian adults: prevalence and associated disability. J Manipulative Physiol Ther, 2004 May, 27(4): 238-244.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Hoy D, March L, Brooks P, Blyth F, Woolf A, Bain C et al. The global burden of low back pain: estimates from the Global Burden of Disease 2010 study. Ann Rheum Dis, 2014 Jun, 73(6): 968-974.</mixed-citation><mixed-citation xml:lang="en">Hoy D, March L, Brooks P, Blyth F, Woolf A, Bain C et al. The global burden of low back pain: estimates from the Global Burden of Disease 2010 study. Ann Rheum Dis, 2014 Jun, 73(6): 968-974.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Хроническая боль в спине. Клинические рекомендации. Приняты на IV конгрессе врачей первичного звена здравоохранения Юга России, IX конференции врачей общей практики (семейных врачей) Юга России 7 ноября 2014 г., Ростов-на-Дону. http://sevgb6.ru/doc/ klinicheskie-rekomendacii/xronicheskaya-bol-v-spine.pdf.</mixed-citation><mixed-citation xml:lang="en">Chronic back pain. Clinical guidelines. Adopted at the 4th Congress of Primary Health Care Professionals of the South of Russia, 9th Conference of General Practitioners (Family Physicians) of the South of Russia, November 7, 2014, Rostov-on-Don. http:// sevgb6.ru/doc/klinicheskie-rekomendacii/xronicheskaya-bol-v-spine.pdf.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Левин О.С. Эффективность Алфлутопа при хронической вертеброгенной люмбоишиалгии по данным двойного слепого плацебо-контролируемого исследования. Научно-практическая ревматология, 2004, 4: 80-84.</mixed-citation><mixed-citation xml:lang="en">Levin OS. Efficacy of alflutop in chronic vertebrogenic lumbosciagia based on the results of the double-blind, placebo-controlled study. Nauchno-Prakticheskaya Revmatologiya, 2004, 4: 80-84.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Ковальчук В.В. Применение препарата Алфлутоп как возможность повышения эффективности традиционной терапии больных, страдающих болями в спине. РМЖ, 2014, 10: 777-781.</mixed-citation><mixed-citation xml:lang="en">Kovalchuk VV. Use of alflutop as an opportunity to increase the efficacy of conventional therapy for patients with back pain. BC, 2014, 10: 777-781.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Ходырев В.Н., Голикова Л.Г. Клиническая эффективность Алфлутопа при остеохондрозе позвоночника (12-месячное исследование). Научно-практическая ревматология, 2004, 5: 33-36.</mixed-citation><mixed-citation xml:lang="en">Khodyrev VN, Golikova LG. Clinical efficacy of alflutop in osteochondrosis of the spine (12-month study). Nauchno-Prakticheskaya Revmatologiya, 2004, 5: 33-36.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Данилов А.Б., Жаркова Т.Р., Ахметджанова Л.Т. Анальгетические свойства препарата Алфлутоп в лечении хронической боли в спине. Consi lium Medicum. Неврология и ревматология. (Прил.), 2010, 2: 26-29.</mixed-citation><mixed-citation xml:lang="en">Danilov AB, Zharkova TR, Akhmetzhanova LT. Analgesic effects of Alflutop therapy for chronic back pain. Consilium Medicum. Nevrologiya i Revmatologiya. (Appendix), 2010, 2: 26-29.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
